|
|
|
| Clinical Effect of Neuropathic factor in the treatment of Cerebral Infarction and its effect on plasma D-D, TXB2 and BNP |
| YIN Xingzhi |
| The Fifth People's Hospital of Qinghai, Qinghai Xining 810007, China |
|
|
|
|
Abstract Objective: To study the efficacy of rat neurotrophic factor in the treatment of cerebral infarction and its effects on plasma D-D, TXB2 and BNP. Methods: From April 2015 to March 2016, 120 patients with cerebral infarction were selected in our hospital, those patients were randomly divided into control group (60 cases) and experimental group (60 cases) according to simple random grouping. The control group was treated with conventional drugs. The experimental group were given nerve growth factor to complete the treatment on the basis of control group. The clinical efficacy, daily living ability (ADL) and neurological score, plasma D-D, TXB2 and BNP levels were compared between the two groups. Results: After treatment, the total effective rate was 83.33% in the experimental group was significantly higher than that in the control group 70.00% (P<0.05). The scores of ADL in the experimental group were significantly higher than those in the control group [(64.60±5.13)points VS(54.51±5.33)points] (P<0.05), NIHSS score was significantly lower than that of the control group [(9.49±1.03)points VS (15.04±1.17) points] (P<0.05). The levels of DD, TXB2 and BNP in the test group were significantly lower than those in the control group [(0.47±0.04)mg/L,(46.14±3.88)ng/L,(10.93±1.29)pg/ml VS(1.23±0.15)mg/L, (68.80±6.19)ng/L,(18.56±2.07)pg/ml](P<0.05). Conclusion: The treatment of neurological growth factor in patients with cerebral infarction can effectively reduce the levels of plasma D-D, TXB2 and BNP, improve the clinical symptoms of patients, the clinical efficacy is good and the safety is high.
|
|
|
|
|
|
[1] Wei Sun, Guangsheng Li, Xiangjun Zeng,et al. Clinical and imaging characteristics of cerebral Infarction in patients with nonvalvular atrial fibrillation combined with cerebral artery stenosis[J].Atheroscler Thromb,2018, 25(8): 720~732.
[2] Yajuan Chen, Jinsheng Zeng, Xingrui Xie, et al. Clinical features of systemic cancer patients with acute cerebral infarction and its underlying pathogenesis[J]. Int Clin Exp Med, 2015,8(3): 4455~4463.
[3] Shu-Jin Wang, Zhong-Sen Qu, Qing-De Zhang,et al. The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction[J]. Int Clin E,2015, 8(8): 13017~13027.
[4] 中国急性缺血性脑卒中诊治指南2010[J].中国临床医生,2011,39(3):67~73.
[5] 张明园,何燕玲.精神科评定量表手册[M].湖南科学技术出版社,2015.231~258.
[6] 侯东哲,张颖,巫嘉陵,等.中文版美国国立卫生院脑卒中量表的信度与效度研究[J].中华物理医学与康复杂志,2012,34(5):372~374.
[7] Jaehyun Shim, Byung Kook Kwak, Jisung Jung, et al. Evaluation of engraftment of superparamagnetic iron oxide-labeled mesenchymal stem cells using three-dimensional reconstruction of magnetic resonance imaging in photothrombotic cerebral infarction models of rats[J]. Korean Radiol,2015, 16(3): 575~585.
[8] Hisataka Sasao, Hidetoshi Fujiwara, Naruyoshi Horiuchi,et al. Comparison of long-term clinical outcomes after drug-eluting stent implantation in patients with coronary artery disease with and without prior cerebral infarction[J]. Ann Vasc Dis, 2015, 8(2): 79~86.
[9] Bo Zhang, Dan Wang, Tie-Feng Ji,et al. Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-κB signaling pathway in a rat model[J]. Oncotarget, 2017, 8(10): 17347~17359.
[10] Jie Wang, Xiao-Du Yu, Guang-Qin Li. Comparative study on short-term and long-term prognostic determinants in patients with acute cerebral infarction[J]. Int Clin Exp Med, 2015, 8(6): 9855~9861.
[11] Shaojun Wang, Jun Zhou, Weijie Kang,et al. Tocilizumab inhibits neuronal cell apoptosis and activates STAT3 in cerebral infarction rat model[J]. Bosn Basic Med Sci,2016,16(2): 145~150. |
|
|
|
2019, Vol. 25 
